臨床眼科65巻4号

2011年04月発行

特集 第64回日本臨床眼科学会講演集（2） 原著

滲出型加齢黄斑変性に対するラニビズマブ硝子体投与併用光線力学療法の6か月経過

著者： 中村友子¹ 宮腰晃央² 藤田和也¹ 藤野貴啓¹ 三原美晴¹ 柚木達也¹ 御手洗慶一¹ 柳沢秀一郎¹ 淵澤千春¹ 林篤志¹

所属機関： ¹富山大学大学院医学薬学研究部眼科学講座 ²高岡市民病院眼科

ページ範囲：P.481 - P.485

要約　目的：滲出型加齢黄斑変性（AMD）に対するラニビズマブ硝子体投与併用光線力学療法（PDT）の結果の報告。対象と方法：滲出型AMD 45例45眼を対象とした。男性36眼，女性9眼で，年齢は53～90歳（平均72歳）である。6か月以上の経過を追跡した。結果：ラニビズマブの平均硝子体投与回数は2.56回，PDTの平均回数は1.10回であった。平均logMAR値は治療前0.57，治療後0.34と有意に改善し（p＜0.01），平均中心窩網膜厚は治療前428μm，治療後248μmと有意に減少した（p＜0.01）。治療6か月後におけるlogMAR値0.3以上の視力変化では改善40.0％，維持57.8％，悪化2.2％であった。結論：AMDに対するラニビズマブ硝子体投与併用光線力学療法は，短期的に視力の改善および滲出性変化の改善に有効である。

参考文献

1）Zarbin MA：Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol　112：598-614, 2004

2）Radouil T, Ton L, Kai-Ming Z et al：Ocular changes after photodynamic therapy. Invest Ophthalmol Vis Sci　47：377-385, 2006

3）Lai TY, Chan WM, Lam DS：Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy. Am J Ophthalmol　137：826-833, 2004

4）Kvanta A, Algvere PV, Berglin L et al：Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci　3：1929-1934, 1996

5）Husain D, Kim I, Gauthier D et al：Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol　123：509-516, 2005

6）Ju M, Mailhos C, Bradley J et al：Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization. Invest Ophthalmol Vis Sci　49：662-670, 2008

7）Mataix J, Palacios E, Carmen DM et al：Combined ranibizumab and photodynamic therapy to treat exudative age-related macular degeneration：an option for improving treatment efficiency. Retina　30：1190-1196, 2010

8）Kumar A, Gopalakrishnan K, Sinha S et al：Combination photodynamic therapy and intravitreal ranibizumab in neovasucular AMD in a north Indian population：a pilot study. Retina　28：1296-1301, 2008

9）Spielberg L, Leys A：Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy：the TORPEDO trial at 2 years. Graefes Arch Clin Exp Ophthalmol　248：943-956, 2010

10）Tano Y, Ophthalmic PDT Study Group：Guidelines for PDT in Japan. Ophthalmology　115：585-585, e6, 2008

11）Japanese Age-Related Macular Degeneration Trial（JAT）Study Group：Japanese Age-related Macular Degeneration Trial：1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol　136：1049-1061, 2003

12）Japanese Age-Related Macular Degeneration Trial（JAT）Study Group：Photodynamic therapy with verteporfin in japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration（AMD）：results of the Japanese AMD Trial（JAT）extension. Jpn J Ophthalmol　52：99-107, 2008

13）Tator O, Adam A, Shinoda K et al：Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol　142：95-104, 2006

14）Boyer DS, Antoszyk AN, Awh CC et al：Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology　114：246-252, 2007

15）Kaiser PK, Blodi BA, Shapiro H et al：Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology　114：1868-1875, 2007

16）Kaiser PK, Brown DM, Zhang K et al：Ranibizumab for predominantly classic neovascular age-related macular degeneration：subgroup analysis of first-year ANCHOR results. Am J Ophthalmol　144：850-857, 2007

17）Heier JS, Boyer DS, Ciulla TA et al：Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration：year 1 results of the FOCUS study. Arch Ophthalmol　124：1532-1542, 2006

18）Gomi F, Ohji M, Sayanagi K et al：One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology　115：141-146, 2008

19）Fung AE, Lalwani GA, Rosenfeld PJ et al：An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab（Lucentis）for neovascular age-related macular degeneration. Am J Ophthalmol　143：566-583, 2007

20）Otani A, Sasahara M, Yodoi Y et al：Indocyanine green angiography：guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol　144：7-14, 2007